The prevalence of Congenital Hyperinsulinism (CHI) is estimated to be around 1 in 25,000 to 50,000 live births worldwide. This rare genetic disorder causes excessive insulin production in infants, leading to low blood sugar levels and potential long-term complications. CHI can result from various gene mutations affecting insulin regulation in the pancreas. Early diagnosis and prompt treatment are crucial to prevent brain damage and other health issues associated with hypoglycemia. Due to its low prevalence, specialized medical expertise and resources are often required to manage this condition effectively.
Congenital Hyperinsulinism (CHI) is a rare genetic disorder characterized by excessive insulin production in the pancreas, leading to low blood sugar levels. It is estimated to affect approximately 1 in every 50,000 to 1 in every 250,000 live births worldwide, making it a relatively uncommon condition.
CHI can present in two main forms: focal and diffuse. Focal CHI occurs when only a small part of the pancreas is affected, while diffuse CHI involves the entire pancreas. The prevalence of each form varies, with focal CHI being more common.
CHI can have significant consequences for affected individuals: it can cause seizures, developmental delays, and in severe cases, permanent brain damage. Prompt diagnosis and appropriate management are crucial to prevent long-term complications.
Due to its rarity, CHI often requires specialized medical expertise: diagnosis involves genetic testing, imaging studies, and biochemical assessments. Treatment options include medications, dietary modifications, and in some cases, surgical intervention.
Support and awareness for CHI are important: organizations and foundations dedicated to CHI provide resources, research funding, and support networks for affected individuals and their families.